Peptides in aesthetic medicine — beyond the skincare aisle

Aesthetic medicine and peptide biology have been tangled together for decades, and the relationship is more layered than either a skincare label or a wellness protocol usually conveys.

To understand what's actually happening, it helps to map the territory in tiers, because the evidence and the mechanism are genuinely different depending on which tier you're in.

The topical cosmetic tier is where most people encounter peptides first. GHK-Cu — a copper tripeptide — is one of the most studied topical peptides, with a research arc extending back to Loren Pickart's work in the 1970s. In fibroblast cultures, GHK-Cu stimulates collagen and glycosaminoglycan synthesis. It appears to promote wound healing, reduce inflammation, and have antioxidant effects. In human skin, it has been associated in smaller studies with improvements in skin firmness, reduction of fine lines, and improvements in skin texture over sustained use. These are real effects at the mechanistic level. The honest qualification is that the magnitude of effects in human cosmetic trials is modest, the study sizes are small, and the dose and formulation that actually reaches the dermis from a topical product depends enormously on how the product was formulated — penetration enhancers, molecular weight, vehicle, and pH all affect bioavailability in ways that most product labels tell you nothing about.

PAL-GHK (palmitoyl tripeptide-1) and palmitoyl tetrapeptide-7 are the ingredients behind Matrixyl, a branded peptide complex found in numerous premium moisturizers and serums. The palmitate chain is added to improve skin penetration — the lipid makes the peptide more fat-soluble and therefore more able to traverse the skin's lipid-rich outer barrier. Research on palmitoyl peptides has shown in vitro effects on collagen synthesis and matrix remodeling. The clinical translation — what the skin actually looks like after twelve weeks of use — shows modest improvement signals in sponsored trials. The honest framing here is that Matrixyl and similar peptide complexes are better than many cosmetic actives and worse than the marketing implies.

Snap-8 and similar acetyl octapeptide-3 compounds are sometimes marketed as topical analogs of botulinum toxin — peptides that inhibit the SNARE protein complex involved in neurotransmitter release at the neuromuscular junction, theoretically reducing muscle contraction and the repeated movement that deepens expression lines over time. The mechanism is plausible in theory. Whether topically applied peptides actually penetrate to the neuromuscular junction at concentrations sufficient to produce this effect is extremely uncertain, and the clinical trials are primarily manufacturer-sponsored with small sample sizes and modest effect sizes. This is a category where the gap between the mechanistic story and the clinical evidence is significant.

Copper peptides more broadly — beyond GHK-Cu specifically — influence the behavior of skin cells through copper's role as a cofactor in enzymes involved in collagen cross-linking and antioxidant defense. Lysyl oxidase, which cross-links collagen and elastin fibers into functional structural proteins, is a copper-dependent enzyme. Superoxide dismutase, which quenches reactive oxygen species that degrade skin proteins, is also copper-dependent. The logic of supporting these pathways topically has biological validity; the practical effect depends on formulation, bioavailability, and baseline skin condition.

Growth factor mimetics in topical products — peptide sequences designed to mimic or stimulate the action of EGF, TGF-beta, or IGF-1 in the skin — occupy a similarly ambiguous space. Growth factors applied topically face substantial barriers to reaching the receptor-expressing cells in the dermis, and their molecular size generally works against penetration. Some products use conditioned media — media in which growth factor-producing cells have been cultured — containing a cocktail of secreted factors. Whether growth factor-containing topical products produce meaningful dermal effects is an open question; some providers and patients report subjective improvements, and the mechanism is at least coherent in principle.

The procedural cosmetic tier represents a step up in both evidence and invasiveness. Mesotherapy — the injection of cocktails of active compounds including peptides, vitamins, amino acids, and sometimes hyaluronic acid directly into the dermis or subcutaneous space — has been practiced in aesthetic medicine for decades, primarily in Europe and Latin America. The rationale is that bypassing the topical penetration problem delivers active compounds where they can actually work. Peptide mesotherapy protocols vary widely — different practitioners use different cocktail compositions, concentrations, and injection techniques — and the evidence base is heterogeneous and largely not based on large randomized controlled trials. Some practitioners use compounded GHK-Cu, amino acid mixtures, and other peptide-containing solutions as superficial injections for skin texture and tone support, hair follicle support (scalp mesotherapy for hair loss is a distinct category with its own evidence picture), and facial skin quality. The consistency of outcomes varies considerably with practitioner skill and product quality.

The systemic peptide tier with aesthetic effects is where the more physiologically meaningful — and more medically significant — peptide biology sits.

BPC-157 has been used in some protocols partly for its systemic healing and anti-inflammatory effects, with the skin quality and recovery improvements as downstream benefits rather than primary targets. The anti-inflammatory dimension reduces the low-grade systemic inflammation that accelerates skin aging; the wound-healing biology is relevant to the repair processes that maintain skin structure.

GH-axis peptides — sermorelin, ipamorelin, CJC-1295 — have well-characterized effects on body composition and tissue quality that have obvious aesthetic relevance. Growth hormone increases collagen synthesis through IGF-1-mediated fibroblast stimulation; GH also supports lipolysis and lean mass preservation, which affects how the body looks and how skin drapes over the underlying tissue structure. In midlife adults with declining GH pulse amplitude, GH-axis support may help support skin density, hair quality, and body composition in ways that are genuinely visible. These are not cosmetic compounds in the topical sense — they are compounds with systemic effects that include aesthetic outcomes, which is a meaningfully different category. They require a prescribing provider, individual assessment, and appropriate monitoring.

GHK-Cu administered systemically — as a subQ injection rather than topically — represents an attempt to deliver the compound at concentrations that topical application cannot achieve and to allow systemic distribution to skin and hair follicles. The preclinical and in vitro evidence for GHK-Cu's effects on fibroblasts and collagen is strong. Whether systemic administration produces meaningfully better aesthetic outcomes than well-formulated topical use is not established in human trials, but the logic of bypassing topical penetration limitations is coherent.

The GLP-1 intersection with aesthetic medicine has become one of the most visible peptide-aesthetics intersections in recent years, and it runs in an unexpected direction. GLP-1 agonists — semaglutide and tirzepatide particularly — have produced dramatic weight loss results for many patients. Dramatic weight loss, achieved relatively rapidly, produces facial volume loss along with body fat reduction. The face ages partly through volume loss — the fat compartments that give a youthful face its three-dimensional structure redistribute and diminish over time — and rapid weight loss accelerates this process. The aesthetic medicine community has responded with increased demand for facial filler (hyaluronic acid, biostimulators like Sculptra and Radiesse) and skin-tightening procedures (radiofrequency microneedling, high-intensity focused ultrasound, laser resurfacing) in patients on GLP-1 therapy. The term "Ozempic face" emerged as shorthand for this phenomenon. This is not a reason to avoid GLP-1 therapy if it's appropriate — the metabolic benefits can substantially outweigh the facial volume concern — but it is a reason to plan proactively, to have an aesthetic medicine evaluation before or during significant weight loss, and to consider body composition-preserving approaches (adequate protein, resistance training) to mitigate lean mass loss alongside fat loss.

The foundational aesthetic medicine interventions have evidence that substantially exceeds anything in the peptide tier, and they belong in any honest discussion of what actually produces visible results.

Sunscreen is the single most evidence-supported anti-aging intervention available without a prescription. UV radiation drives photoaging — dermal collagen degradation, pigmentation changes, epidermal thickening — through mechanisms that are well-characterized and cumulatively significant. Daily broad-spectrum SPF 30-50+, applied consistently, prevents the UV damage that is the primary driver of premature skin aging in most people. Retinoids — tretinoin, retinol — have the most robust evidence of any topical active for skin aging. Tretinoin at prescription strength increases collagen synthesis, normalizes cell turnover, reduces hyperpigmentation, and has decades of randomized controlled trial data. It works through retinoic acid receptors in keratinocytes and fibroblasts in ways that are well-characterized and well-replicated. The comparison between topical peptide evidence and topical retinoid evidence is not close. Consistent moisturization supports barrier function and reduces the transepidermal water loss that accelerates stratum corneum aging. Sleep, hydration, and not smoking are non-negotiable foundations.

The procedural aesthetic medicine tier — neurotoxins (onabotulinumtoxinA, abobotulinumtoxinA), hyaluronic acid and biostimulator fillers, energy-based devices including fractional laser, radiofrequency microneedling, and high-intensity focused ultrasound — has evidence for visible effects that is far stronger than any peptide intervention. These procedures do not compete with peptide approaches for the same biological mechanism; they address different structural and surface issues. Peptides are not substitutes for neurotoxin if dynamic lines are the concern. Peptides are not substitutes for filler if volume loss is the concern. The honest integration is that peptide approaches may support the underlying skin biology — the collagen, the barrier, the inflammatory tone, the cellular energy — while procedural aesthetics addresses the structural outcomes that require more direct intervention. They are complementary categories, not competing ones.

Evaluating aesthetic peptide claims critically requires asking a consistent set of questions: Is the evidence in vitro, animal, or human? Are the human studies randomized, controlled, and blinded, or are they open-label self-assessment? Who funded the research? What was the effect size, and how does it compare to the comparator (sunscreen, retinoid, a procedure)? Is the peptide actually reaching the relevant tissue at the applied dose and formulation? These questions don't disqualify peptide approaches — some compounds have coherent mechanisms and real (if modest) evidence. They do calibrate the expectation to something more useful than what most product marketing sets.

An aesthetic medicine provider who is familiar with both procedural options and the emerging peptide and biologic support tier can help map which interventions address which specific concerns and how they might work together. That conversation is more useful than choosing between an overpriced serum and an unsupervised systemic peptide protocol. The skin that shows up at 45 or 55 reflects decades of UV exposure, sleep quality, inflammatory burden, hormonal changes, and genetic predisposition. The interventions that move the needle on that picture are specific. Understanding which ones those are — and what the evidence actually says — is the starting point.